K. Wilner
Pfizer (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Pharmacogenetics and Drug Metabolism, Pharmacological Effects and Toxicity Studies, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations(2008)223 cited
- → Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer(2013)92 cited
- → The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function(2000)46 cited
- → Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis(1997)40 cited
- → The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function(2000)36 cited
- → The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid(2000)32 cited
- → Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.(2010)24 cited
- → Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001(2016)16 cited
- → Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Ros1 Gene Rearrangement(2012)16 cited
- → Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib(2016)15 cited